Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13752601 | 1.00 | GHSR (1.00) | GHSRMLNR | |
| SCHEMBL13743360 | 1.00 | GHSR (1.00) | GHSRMLNR | |
| SCHEMBL12134748 | 1.00 | GHSR (1.00) | GHSRMLNR | |
| SCHEMBL8274155 | 1.00 | GHSR (1.00) | GHSRMLNR | |
| SCHEMBL14646711 | 0.91 | GHSR (0.83) | GHSRMLNR | |
| SCHEMBL12134754 | 0.90 | GHSR (1.00) | GHSR | |
| SCHEMBL8274152 | 0.90 | GHSR (1.00) | GHSR | |
| SCHEMBL8274153 | 0.90 | GHSR (1.00) | GHSR | |
| SCHEMBL19248259 | 0.85 | GHSR (0.75) | GHSRMLNR | |
| SCHEMBL13612877 | 0.85 | GHSR (1.00) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180110824-A1 | Macrocyclic Modulators of the Ghrelin Receptor | OCERA THERAPEUTICS, INC. | 2018-04-26 | — | — | US | disclosed |
| EP-2457893-B1 | Intermediates for macrocyclic modulators of the ghrelin receptor | OCERA THERAPEUTICS INC (US) | 2017-08-16 | — | — | EP | disclosed |
| US-8334256-B2 | Pharmaceutical salts of macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. (CA) | 2012-12-18 | — | — | US | disclosed |
| EP-2457893-A1 | Intermediates for macrocyclic modulators of the ghrelin receptor | Tranzyme Pharma, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| EP-2457925-A1 | Process for preparing a macrocyclic modulator of the ghrelin receptor and intermediates | Tranzyme Pharma, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20110288163-A1 | METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | MALLINCKRODT US HOLDINGS LLC | 2011-11-24 | — | — | US | disclosed |
| US-RE42624-E1 | Methods of using macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. (CA) | 2011-08-16 | — | — | US | disclosed |
| US-RE42013-E1 | Macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. (CA) | 2010-12-28 | — | — | US | disclosed |
| US-20090221689-A1 | Macrocyclic Modulators of the Ghrelin Receptor | TRANZYME PHARMA INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090198050-A1 | Macrocyclic Modulators of the Ghrelin Receptor | TRANZYME PHARMA INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090170757-A1 | METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | TRANZYME PHARMA INC. | 2009-07-02 | — | — | US | disclosed |
| US-7491695-B2 | Therapy for endocrime disorders; gastrointestinal disorders; cardiovascular disorders; obesity; central nervous system disorders; antiproliferative agents ; using growth hormone secretagogue receptor | TRANZYME PHARMA INC. (CA) | 2009-02-17 | — | — | US | disclosed |
| US-7476653-B2 | Using growth hormone secretagague receptors; endocrime disorders; gastrointestinal disorders; cardiovascular disorders; central nervous system disorders; antiproliferative agents; antiinflammatory agents | TRANZYME PHARMA, INC. (CA) | 2009-01-13 | — | — | US | disclosed |
| WO-2006009645-A1 | METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | TRANZYME PHARMA, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288163-A1 | METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | GHSR, GHRHR, GIPR | GHSR 1/4885MLNR 42/4885 |
| US-20180110824-A1 | Macrocyclic Modulators of the Ghrelin Receptor | GHSR, GIPR, GHRHR | GHSR 1/4885MLNR 40/4885 |
| US-20090221689-A1 | Macrocyclic Modulators of the Ghrelin Receptor | GHSR, GIPR, GHRHR | GHSR 1/4885MLNR 40/4885 |
| US-20090170757-A1 | METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | GHSR, GHRHR, GIPR | GHSR 1/4885MLNR 42/4885 |
| US-20090198050-A1 | Macrocyclic Modulators of the Ghrelin Receptor | GHSR, GIPR, GHRHR | GHSR 1/4885MLNR 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.